(Reuters) – The U.S. Food and Drug Administration on Wednesday approved Mesoblast’s cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease.

(Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore)

Brought to you by www.srnnews.com